Cargando…

Bactericidal activity of Myrrh extracts and two dosage forms against standard bacterial strains and multidrug-resistant clinical isolates with GC/MS profiling

Myrrh is the resinous exudate obtained by the incision in Commiphora molmol trees (Family Burseraceae). The bactericidal activity of its hexane extract was compared to its essential oil (MEO) using viable count technique against Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (Ps. aerug...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalil, Noha, Fikry, Sahar, Salama, Osama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987268/
https://www.ncbi.nlm.nih.gov/pubmed/31993779
http://dx.doi.org/10.1186/s13568-020-0958-3
_version_ 1783492114531745792
author Khalil, Noha
Fikry, Sahar
Salama, Osama
author_facet Khalil, Noha
Fikry, Sahar
Salama, Osama
author_sort Khalil, Noha
collection PubMed
description Myrrh is the resinous exudate obtained by the incision in Commiphora molmol trees (Family Burseraceae). The bactericidal activity of its hexane extract was compared to its essential oil (MEO) using viable count technique against Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (Ps. aeruginosa). MEO exhibited a better activity with > 99.999% killing of both tested strains after 2 h contact time. MEO was tested using the same technique against four multidrug resistant isolates: S. aureus (MRSA, sputum), Escherichia coli (E. coli, urine), Ps. aeruginosa (wound) and Klebsiella pneumonia (K. pneumonia, sputum). Highest bactericidal activity was observed against Ps. aeruginosa while lowest was against K. pneumonia (99.59 and 54.04% killing, respectively after 2 h contact time). A cream and mouthwash were formulated using 5% v/v MEO. The cream showed a better activity against Ps. aeruginosa than S. aureus (95.11 and 86.76% killing, respectively after 2 h contact time). The in vitro treatment of ca 10(7) CFU/ml S. aureus cells suspended in 10% saliva with the mouthwash produced ca 46% killing within the first 15 min reaching ca 99.999% after 30 min. Cytotoxic studies of both the essential oil and hexane extract on human liver cancer (Hep G2), human breast cancer (MCF-7) and colon cancer cell lines (HCT-116) revealed a promising in vitro activity. Highest activity was recorded for the essential oil on MCF-7 with IC(50) 10.93 ± 0.32 μg/ml. GC/MS analysis allowed the identification of 17 and 9 compounds representing 92.01 and 99.99% of the hexane extract and essential oil, respectively. Furano-eudesma-1,3-diene (15.99%) and 2-acetoxy-furano-diene (26.82%) were the major identified compounds in the hexane extract and essential oil, respectively. These results indicate that Myrrh essential oil is a promising antibacterial and cytotoxic agent that can be formulated in suitable dosage forms.
format Online
Article
Text
id pubmed-6987268
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-69872682020-02-11 Bactericidal activity of Myrrh extracts and two dosage forms against standard bacterial strains and multidrug-resistant clinical isolates with GC/MS profiling Khalil, Noha Fikry, Sahar Salama, Osama AMB Express Original Article Myrrh is the resinous exudate obtained by the incision in Commiphora molmol trees (Family Burseraceae). The bactericidal activity of its hexane extract was compared to its essential oil (MEO) using viable count technique against Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (Ps. aeruginosa). MEO exhibited a better activity with > 99.999% killing of both tested strains after 2 h contact time. MEO was tested using the same technique against four multidrug resistant isolates: S. aureus (MRSA, sputum), Escherichia coli (E. coli, urine), Ps. aeruginosa (wound) and Klebsiella pneumonia (K. pneumonia, sputum). Highest bactericidal activity was observed against Ps. aeruginosa while lowest was against K. pneumonia (99.59 and 54.04% killing, respectively after 2 h contact time). A cream and mouthwash were formulated using 5% v/v MEO. The cream showed a better activity against Ps. aeruginosa than S. aureus (95.11 and 86.76% killing, respectively after 2 h contact time). The in vitro treatment of ca 10(7) CFU/ml S. aureus cells suspended in 10% saliva with the mouthwash produced ca 46% killing within the first 15 min reaching ca 99.999% after 30 min. Cytotoxic studies of both the essential oil and hexane extract on human liver cancer (Hep G2), human breast cancer (MCF-7) and colon cancer cell lines (HCT-116) revealed a promising in vitro activity. Highest activity was recorded for the essential oil on MCF-7 with IC(50) 10.93 ± 0.32 μg/ml. GC/MS analysis allowed the identification of 17 and 9 compounds representing 92.01 and 99.99% of the hexane extract and essential oil, respectively. Furano-eudesma-1,3-diene (15.99%) and 2-acetoxy-furano-diene (26.82%) were the major identified compounds in the hexane extract and essential oil, respectively. These results indicate that Myrrh essential oil is a promising antibacterial and cytotoxic agent that can be formulated in suitable dosage forms. Springer Berlin Heidelberg 2020-01-28 /pmc/articles/PMC6987268/ /pubmed/31993779 http://dx.doi.org/10.1186/s13568-020-0958-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Khalil, Noha
Fikry, Sahar
Salama, Osama
Bactericidal activity of Myrrh extracts and two dosage forms against standard bacterial strains and multidrug-resistant clinical isolates with GC/MS profiling
title Bactericidal activity of Myrrh extracts and two dosage forms against standard bacterial strains and multidrug-resistant clinical isolates with GC/MS profiling
title_full Bactericidal activity of Myrrh extracts and two dosage forms against standard bacterial strains and multidrug-resistant clinical isolates with GC/MS profiling
title_fullStr Bactericidal activity of Myrrh extracts and two dosage forms against standard bacterial strains and multidrug-resistant clinical isolates with GC/MS profiling
title_full_unstemmed Bactericidal activity of Myrrh extracts and two dosage forms against standard bacterial strains and multidrug-resistant clinical isolates with GC/MS profiling
title_short Bactericidal activity of Myrrh extracts and two dosage forms against standard bacterial strains and multidrug-resistant clinical isolates with GC/MS profiling
title_sort bactericidal activity of myrrh extracts and two dosage forms against standard bacterial strains and multidrug-resistant clinical isolates with gc/ms profiling
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987268/
https://www.ncbi.nlm.nih.gov/pubmed/31993779
http://dx.doi.org/10.1186/s13568-020-0958-3
work_keys_str_mv AT khalilnoha bactericidalactivityofmyrrhextractsandtwodosageformsagainststandardbacterialstrainsandmultidrugresistantclinicalisolateswithgcmsprofiling
AT fikrysahar bactericidalactivityofmyrrhextractsandtwodosageformsagainststandardbacterialstrainsandmultidrugresistantclinicalisolateswithgcmsprofiling
AT salamaosama bactericidalactivityofmyrrhextractsandtwodosageformsagainststandardbacterialstrainsandmultidrugresistantclinicalisolateswithgcmsprofiling